{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:57:25Z","timestamp":1780563445165,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ajp.2022.103322","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T22:34:05Z","timestamp":1668206045000},"page":"103322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report"],"prefix":"10.1016","volume":"80","author":[{"given":"Laya","family":"Jalilian Khave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"Noori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afarin","family":"Rahimi-Movaghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-4348","authenticated-orcid":false,"given":"Alireza","family":"Noroozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajp.2022.103322_bib1","first-page":"700","article-title":"Abuse liability of gabapentin in the Saudi population after the pregabalin restriction: A cross-sectional study","volume":"16","author":"Alkhalaf","year":"2021","journal-title":"J. Taibah Univ. Med Sci."},{"issue":"10","key":"10.1016\/j.ajp.2022.103322_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin. Pharm."},{"issue":"12","key":"10.1016\/j.ajp.2022.103322_bib3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.ajp.2022.103322_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00228-010-0920-4","article-title":"Earlier discovery of pregabalin's dependence potential might have been possible","volume":"67","author":"Caster","year":"2011","journal-title":"Eur. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.ajp.2022.103322_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/2049463720912496","article-title":"Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice","volume":"14","author":"Chincholkar","year":"2020","journal-title":"Br. J. Pain."},{"issue":"4","key":"10.1016\/j.ajp.2022.103322_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/10550887.2021.1907502","article-title":"Gabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report","volume":"39","author":"Deng","year":"2021","journal-title":"J. Addict. Dis."},{"issue":"1","key":"10.1016\/j.ajp.2022.103322_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ajp.2022.103322_bib8","unstructured":"France 24. (2021). Prices soar at opium market in Taliban-ruled Afghanistan. September 29, 2021. Available from:\u3008https:\/\/www.france24.com\/en\/live-news\/20210929-prices-soar-at-opium-market-in-taliban-ruled-afghanistan\u3009."},{"issue":"5","key":"10.1016\/j.ajp.2022.103322_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern. Med."},{"issue":"11","key":"10.1016\/j.ajp.2022.103322_bib10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2146\/ajhp090313","article-title":"Withdrawal symptoms after gabapentin discontinuation","volume":"67","author":"Hellwig","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ajp.2022.103322_bib11","unstructured":"Iran Food and Drug Organization (FDO). (2020a). National Medications Statistics in 2020. Deputy for Food and Drug. Ministry of Health and Medical Education. Available from: \u3008https:\/\/www.fda.gov.ir\/fa\u3009."},{"key":"10.1016\/j.ajp.2022.103322_bib12","unstructured":"Iran Food and Drug Organization (FDO). (2020b). National Formulary of Iran. Deputy for Food and Drug. Ministry of Health and Medical Education. Available from: \u3008http:\/\/irc.fda.gov.ir\/nfi\/Detail\/21893\u3009 \u3008http:\/\/irc.fda.gov.ir\/NFI\/Search?Term=pregabalin+\u3009."},{"key":"10.1016\/j.ajp.2022.103322_bib13","unstructured":"Iran Food and Drug Organization (FDO). (2017). National Medications Statistics in 2017. Deputy for Food and Drug. Ministry of Health and Medical Education.Available from: \u3008https:\/\/www.fda.gov.ir\/fa\u3009."},{"issue":"4","key":"10.1016\/j.ajp.2022.103322_bib14","first-page":"314","article-title":"Gabapentin-induced delirium and dependence","volume":"15","author":"Kruszewski","year":"2009","journal-title":"J. Psychiatr. Pr."},{"issue":"2","key":"10.1016\/j.ajp.2022.103322_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-012-2251-x","article-title":"A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors","volume":"136","author":"Lavigne","year":"2012","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"10.1016\/j.ajp.2022.103322_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.semcdb.2006.09.003","article-title":"alpha2delta and the mechanism of action of gabapentin in the treatment of pain","volume":"17","author":"Maneuf","year":"2006","journal-title":"Semin Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.ajp.2022.103322_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199710000-00012","article-title":"Gabapentin abuse in a cocaine user: implications for treatment?","volume":"17","author":"Markowitz","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.ajp.2022.103322_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4140\/TCP.n.2019.490","article-title":"Gabapentin: change is in the Wind","volume":"34","author":"McPherson","year":"2019","journal-title":"Sr Care Pharm."},{"issue":"3","key":"10.1016\/j.ajp.2022.103322_bib19","first-page":"229","article-title":"Gabapentin: abuse, dependence, and withdrawal","volume":"50","author":"Mersfelder","year":"2016","journal-title":"Ann. Pharm."},{"issue":"4","key":"10.1016\/j.ajp.2022.103322_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00002826-200107000-00011","article-title":"Gabapentin withdrawal syndrome","volume":"24","author":"Norton","year":"2001","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2022.103322_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamainternmed.2013.11973","article-title":"Gabapentin: a new addition to the armamentarium for alcohol dependence?","volume":"174","author":"Nunes","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ajp.2022.103322_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Health Policy"},{"key":"10.1016\/j.ajp.2022.103322_bib23","article-title":"Other Cognitive and Mental Disorders due to Another Medical Condition","volume":"Vol. 1","author":"Prins","year":"2017"},{"issue":"5","key":"10.1016\/j.ajp.2022.103322_bib24","article-title":"Abuse of combinations of gabapentin and quetiapine","volume":"16","author":"Reeves","year":"2014","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"6","key":"10.1016\/j.ajp.2022.103322_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2022.103322_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-199904000-00019","article-title":"Catatonia following gabapentin withdrawal","volume":"19","author":"Rosebush","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.ajp.2022.103322_bib27","first-page":"1160","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addict. 2016 Jul."},{"key":"10.1016\/j.ajp.2022.103322_bib28","series-title":"Sanctions and Illicit Drugs in Iran. The SAIS Initiative for Research on Contemporary Iran","author":"Soderholm","year":"2020"},{"issue":"2","key":"10.1016\/j.ajp.2022.103322_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.yebeh.2007.04.007","article-title":"Conversions between monotherapies in epilepsy: expert consensus","volume":"11","author":"St Louis","year":"2007","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ajp.2022.103322_bib30","article-title":"Anticonvulsants: Gabapentin, Topiramate, Tiagabine, Levetiracetam, Zonisamide, and Pregabalin","volume":"Vol. 2","author":"Wang","year":"2017"},{"key":"10.1016\/j.ajp.2022.103322_bib31","series-title":"StatPearls [Internet]","article-title":"Gabapentin","author":"Yasaei","year":"2022"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822003203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822003203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:46:12Z","timestamp":1761756372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201822003203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"alternative-id":["S1876201822003203"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103322","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103322"}}